IMGN632 - Emerging Insight and Market Forecast - 2030

“IMGN632 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Blastic Plasmacytoid Dendritic Cell Neoplasm in 7 Major Markets. A detailed picture of the IMGN632 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview
IMGN632 is a CD123-targeting antibody-drug conjugate (ADC) comprising a novel anti-CD123 antibody coupled, via a peptide linker, to a unique DNA-alkylating cytotoxic payload of the recently developed IGN (indoline benzodiazepine pseudo dimer) class. When delivered to a target cell via the anti-CD123 antibody, the IGN payload alkylates DNA without crosslinking, which kills the CD123-expressing target cell. The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.

Scope of the report
The report provides insights into:
● A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
● Elaborated details on regulatory milestones and other development activities have been provided in this report.
● The report also highlights the drug research and development activity details across the United States, Europe and Japan.
● The report also covers the patents information with an expiry timeline around IMGN632.
● The report contains forecasted sales for IMGN632 till 2030.
● Comprehensive coverage of the Early-stage emerging therapies (Phase I/II) for Blastic Plasmacytoid Dendritic Cell Neoplasm.
● The report also features the SWOT analysis with analyst insights and key findings of IMGN632.

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMGN632 Analytical Perspective by DelveInsight
● In-depth IMGN632 Market Assessment
This report provides a detailed market assessment of IMGN632 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

● IMGN632 Clinical Assessment
The report provides the clinical trials information of IMGN632 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
● In the coming years, the market scenario for Blastic Plasmacytoid Dendritic Cell Neoplasm is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
● The companies and academics are working to assess challenges and seek opportunities that could influence IMGN632 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
● Other emerging products for Blastic Plasmacytoid Dendritic Cell Neoplasm are giving market competition to IMGN632 and launch of late-stage emerging therapies in the near future will significantly impact the market.
● A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of IMGN632.
● Our in-depth analysis of the forecasted sales data of IMGN632 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IMGN632.

Key Questions
• Which company is developing IMGN632 along with the phase of the clinical study?
• What is the technology utilized in the development of IMGN632?
• What is the product type, route of administration and mechanism of action of IMGN632?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMGN632 development?
• What are the key designations that have been granted to IMGN632?
• What is the forecasted market scenario of IMGN632?
• What is the history of IMGN632 and what is its future?
• What is the forecasted sales of IMGN632 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to IMGN632?
• Which are the late-stage emerging therapies under development for the treatment of the Blastic Plasmacytoid Dendritic cells neoplasm?